Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.

READ FULL ARTICLE Curated publisher From Mdlinx